SCHEMBL13893284

SCHEMBL13893284

CCCC(O)C(O)C(O)C(O)CO

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
TDP1 Q9NUW8 1/20 0.58
KDM4E B2RXH2 3/20 0.48
TSHR P16473 1/20 0.43
PDE4A P27815 1/20 0.42
USP2 O75604 1/20 0.39
SLCO1B1 Q9Y6L6 1/20 0.39
CYP2D6 P10635 2/20 0.37
SPHK1 Q9NYA1 1/20 0.37
GMNN O75496 1/20 0.37
POLB P06746 1/20 0.37
THPO P40225 1/20 0.37
MTOR P42345 1/20 0.37
BLM P54132 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
CETP P11597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14147722 1.00 LMNA (0.61) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL17108604 1.00 LMNA (0.61) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL13314743 1.00 LMNA (0.61) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL18744680 0.97 TDP1 (0.63) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL810658 0.97 TDP1 (0.63) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL3138410 0.97 TDP1 (0.63) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL14147721 0.94 LMNA (0.54) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL13296277 0.94 LMNA (0.54) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL17108622 0.94 LMNA (0.54) LMNAL3MBTL1TDP1KDM4ETSHR
SCHEMBL2991748 0.94 LMNA (0.54) LMNAL3MBTL1TDP1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190308943-A1 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS PARION SCIENCES, INC. (US) 2019-10-10 US disclosed
CN-110036148-A Electret fiber sheet material 东丽株式会社 2019-07-19 CN disclosed
US-20170327541-A1 METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS PROTAGONIST THERAPEUTICS, INC. 2017-11-16 US disclosed
US-20170166673-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF ALCON INC. (CH) 2017-06-15 US disclosed
US-9629924-B2 Conjugates of CC-1065 analogs and bifunctional linkers SYNTARGA BV (NL) 2017-04-25 US disclosed
US-9592233-B2 Pharmaceutical combination drug BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2017-03-14 US disclosed
US-9329479-B2 Lithographic printing plate precusor AGFA GRAPHICS NV (BE) 2016-05-03 US disclosed
US-20160022679-A1 PHARMACEUTICAL COMBINATION DRUG BORYUNG PHARMACEUTICAL CO., LTD. (KR) 2016-01-28 US disclosed
WO-2015140527-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2015-09-24 WO disclosed
US-20150168837-A1 LITHOGRAPHIC PRINTING PLATE PRECUSOR ECO3 BV (BE) 2015-06-18 US disclosed
US-8501242-B2 Methods and compositions for treating neoplasia UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2013-08-06 US disclosed
US-20120270911-A1 NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS FERROKIN BIOSCIENCES, INC. (US) 2012-10-25 US disclosed
US-20120202857-A1 NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS FERROKIN BIOSCIENCES, INC. (US) 2012-08-09 US disclosed
US-20120156212-A1 METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION 2012-06-21 US disclosed
US-20120129147-A1 METHOD OF PREPARING CONTROLS FOR GLYCATED HEMOGLOBIN S-A1C DERIVED FROM HEALTHY BLOOD CELLS STRECK, INC. (US) 2012-05-24 US disclosed
US-20120122073-A1 CIS DI-AHL MODIFIED CONTROLS FOR GLYCATED HEMOGLOBIN S-A1C DERIVED FROM HEALTHY BLOOD CELLS STRECK, INC. (US) 2012-05-17 US disclosed
CN-101484458-B Dibenzylidene sorbitol (dbs)-based compounds, compositions and methods for using such compounds MILLIKEN & CO 2011-10-19 CN disclosed
US-20110160257-A1 NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS FERROKIN BIOSCIENCES, INC. (US) 2011-06-30 US disclosed
US-20110105428-A1 HYDROLYSIS RESISTANT ORGANOMODIFIED SILYLATED IONIC SURFACTANTS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2011-05-05 US disclosed
CN-101484458-A Dibenzylidene sorbitol (DBS)-based compounds, compositions and methods for using such compounds MILLIKEN & CO (US) 2009-07-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022679-A1 PHARMACEUTICAL COMBINATION DRUG PCSK9, PCSK6, DPP9 LMNA 802/4885L3MBTL1 4589/4885TDP1 2096/4885
US-20110160257-A1 NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS SLC39A14, SLC40A1, SLC39A11 LMNA 2758/4885L3MBTL1 247/4885TDP1 2149/4885
US-20110105428-A1 HYDROLYSIS RESISTANT ORGANOMODIFIED SILYLATED IONIC SURFACTANTS MLNR, SSTR3, FOXM1 LMNA 1699/4885L3MBTL1 1177/4885TDP1 4499/4885
US-20120202857-A1 NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS SLC39A14, SLC40A1, SLC39A11 LMNA 2510/4885L3MBTL1 271/4885TDP1 2011/4885
US-20120270911-A1 NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS SLC39A14, SLC40A1, SLC39A11 LMNA 2510/4885L3MBTL1 271/4885TDP1 2011/4885
US-20190308943-A1 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS CFTR, SCNN1B, SCN5A LMNA 1942/4885L3MBTL1 4622/4885TDP1 3894/4885
US-20120156212-A1 METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA TYMS, UNG, TYMP LMNA 1559/4885L3MBTL1 2853/4885TDP1 169/4885
US-20170327541-A1 METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS PSMA7, PSMA4, IL4 LMNA 2652/4885L3MBTL1 2637/4885TDP1 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.